Baljit Dheansa

Mr. Baljit Dheansa


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2010 in BMJ
Verified
Journal Article
Closed access
MHMarc-James Hallam
Marc-James Hallam
TCTania Cubison
Tania Cubison
BDBaljit Dheansa
Baljit Dheansa
CIChris Imray
Chris Imray
What factors predispose to frostbite?Factors that predispose to freezing and non-freezing cold injury include military activities, winter sports, and homelessness (box 1).4 In a large retrospective epidemiological review of frostbite injuries sustained over 12 years in the Canadian prairies, individual behaviour was an important contributor to overall risk. Forty six per cent of patients were intoxicated with alcohol, 17% had a psychiatric disorder, and 3% had used illicit drugs.5 Fingers, toes, noses, cheeks, ears, and male genitalia were most commonly affected by frostbite in all groups (in that order).6 A large cross sectional study over 19 years by the US army found that men of Afro-Caribbean descent were four times more likely than white men to sustain cold weather injuries.7Box 1 Predisposing factors General: Unusually cold weather, prolonged exposure to cold, inadequate clothing, inadequate use of appropriate clothing, homelessness, smoking, dehydration, old age, ethnic origin, high altitude Systemic disease: Peripheral vascular disease, diabetes, Raynaud’s disease, sepsis, previous cold injury Psychiatric illness Drugs: β blockers, sedatives, and neuroleptics Trauma: Any immobilising injury, but especially head and spinal injuries and proximal limb trauma that compromises the distal circulation Intoxication: Alcohol and illicit drug use

1 May 2009 in Survey of Ophthalmology
Verified
Journal Article
Closed access
RMRaman Malhotra
Raman Malhotra
ISIjaz Sheikh
Ijaz Sheikh
BDBaljit Dheansa
Baljit Dheansa

1 January 2013 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
JSJustin R. Sharpe
Justin R. Sharpe
SBSimon Booth
Simon Booth
KJKasia Jubin
Kasia Jubin
NJNigel R. Jordan
Nigel R. Jordan
DLDiana J. Lawrence-Watt
Diana J. Lawrence-Watt
BDBaljit Dheansa
Baljit Dheansa
The aim of this study was to measure the pH on the wound surface of 30 burn patients and test the hypothesis that wound surface pH is correlated to he

1 May 2016 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
DMD. Masud
D. Masud
MMM. Moustaki
M. Moustaki
RSR. Staruch
R. Staruch
BDBaljit Dheansa
Baljit Dheansa

1 May 2010 in Burns
Verified
Journal Article
Closed access
SJS. Elizabeth James
S. Elizabeth James
SBSimon Booth
Simon Booth
BDBaljit Dheansa
Baljit Dheansa
DMDawn J. Mann
Dawn J. Mann
MRMichael J. Reid
Michael J. Reid
PGPhilip M. Gilbert
Philip M. Gilbert

31 October 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
ARAmelia Ramon-Lopez
Amelia Ramon-Lopez
JAJane M. Allen
Jane M. Allen
ATAlison H. Thomson
Alison H. Thomson
BDBaljit Dheansa
Baljit Dheansa
SJS. Elizabeth James
S. Elizabeth James
JDJ. Graham Davies
J. Graham Davies
To develop a population model to describe the pharmacokinetics (PK) of intravenous meropenem in adult patients with severe burns and investigate potential relationships between dosage regimens and antimicrobial efficacy. A dose of 1 g every 8 h was administered to adult patients with total body surface area burns of ≥15%. Doses for subsequent courses were determined using results from the initial course and the patient's clinical condition. Five plasma meropenem concentrations were typically measured over the dosage interval on one to four occasions. An open, two-compartment PK model was fitted to the meropenem concentrations using NONMEM and the effect of covariates on meropenem PK was investigated. Monte Carlo simulations investigated dosage regimens to achieve a target T>MIC for ≥40%, ≥60% or ≥80% of the dose interval. Data comprised 113 meropenem concentration measurements from 20 dosage intervals in 12 patients. The parameters were CL (L/h) = 0.196 L/h/kg × [1 − 0.023 × (age − 46)] × [1 − 0.049 × (albumin − 15)], V1 = 0.273 L/kg × [1 − 0.049 × (albumin − 15)], Q = 0.199 L/h/kg and V2 = 0.309 L/kg × [1 – 0.049 × (albumin − 15)]. For a target of ≥80% T>MIC, the breakpoint was 8 mg/L for doses of 1 g every 4 h and 2 g every 8 h given over 3 h, but only 4 mg/L if given over 5 min. Although 1 g 8 hourly should be effective against Escherichia coli and CoNS, higher doses, ideally with a longer infusion time, would be more appropriate for empirical therapy, mixed infections and bacteria with MIC values ≥4 mg/L.